• Asian-Australasian Journal of Animal Sciences
• /
• v.17 no.2
• /
• pp.259-262
• /
• 2004

The ability of Modified Glucomannan (MG) to bind T-2 toxin (T-2) in the gastrointestinal tract has been tested in vivo by feeding 120 five-wk-old broiler chicken with the following six treatment diets, 1) Control diet; 2) Control+MG (0.1%); 3) Control+T-2 (500 ppb); 4) Control+T-2 (500 ppb)+MG (0.1%); 5) Control+T-2 (1,000 ppb) and 6) Control+T-2 (1,000 ppb)+MG (0.1%). Twenty birds were assigned to each treatment group, which had five experimental groups. Four birds of each experimental group were sacrificed at an interval of 30 min i.e. at 0, 30, 60, 90 and 120 min after feeding experimental diets. The whole gut contents of each bird were collected, dried and toxin concentration was determined. Percent T-2 recovered from the gut was significantly lower (p<0.05) in the groups fed MG at all the time intervals. The percent T-2 adsorbed by the MG at different T-2 levels (500 and 1,000 ppb) was 15.97 and 14.77, 22.53 and 22.67, 26.88 and 28.03, and 31.50 and 31.83 at 30, 60, 90 and 120 min, respectively.

• Bulletin of the Korean Chemical Society
• /
• v.26 no.6
• /
• pp.939-942
• /
• 2005

For the detection of cyanobacterial toxin, an Enzyme-linked immunosorbent assay (ELISA) was integrated into a PDMS microchip. The conjugates of microcystin-LR (MCLR) and keyhole limpet hemocyanin (KLH) were adsorbed on the surface of polystyrene beads and these MCLR-KLH polystyrene beads were introduced into a microchamber. MCLR on the surface of polystyrene beads reacted with horseradish peroxides (HRP) conjugated anti-MCLR monoclonal antibody (mAb) which had a competitive reaction with MCLR in water sample. After the enzyme substrate 3,3,5,5-tetramethyl benzidine (TMB) was injected into the chamber and catalyzed by HRP, the color change was detected with a liquid-cord waveguide. This integration shortened the conventional ELISA analysis time from several hours to about 30 min with only 4.2 $\mu$L MCLR sample consuming which was useful for the environmental analysis. More over, troublesome operations required for ELISA could be replaced by simple operations. The microchip based detection system showed a good sensitivity of 0.05 $\mu$g/L and maintained good reliability through its quantitative range with low coefficients of variation (2.5-10.5%).

• Clinical and Experimental Vaccine Research
• /
• v.13 no.2
• /
• pp.155-165
• /
• 2024

Purpose: Pertussis bacteria have many pathogenic and virulent antigens and severe adverse reactions have occurred when using inactivated whole-cell pertussis vaccines. Therefore, inactivated acellular pertussis (aP) vaccines and genetically detoxified recombinant pertussis (rP) vaccines are being developed. The aim of this study was to assess the safety profile of a novel rP vaccine under development in comparison to commercial diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Materials and Methods: The two positive control DTaP vaccines (two- and tri-components aP vaccines) and two experimental recombinant DTaP (rDTaP) vaccine (two- and tri-components aP vaccines adsorbed to either aluminum hydroxide or purified oat beta-glucan) were used. Temperature histamine sensitization test (HIST), indirect Chinese hamster ovary (CHO) cell cluster assay, mouse-weight-gain (MWG) test, leukocytosis promoting (LP) test, and intramuscular inflammatory cytokine assay of the injection site performed for safety assessments. Results: HIST results showed absence of residual pertussis toxin (PTx) in both control and experimental DTaP vaccine groups, whereas in groups immunized with tri-components vaccines, the experimental tri-components rDTaP absorbed to alum showed an ultra-small amount of 0.0066 IU/mL. CHO cell clustering was observed from 4 IU/mL in all groups. LP tests showed that neutrophils and lymphocytes were in the normal range in all groups immunized with the two components vaccine. However, in the tri-components control DTaP vaccine group, as well as two- and tri-components rDTaP with beta-glucan group, a higher monocyte count was observed 3 days after vaccination, although less than 2 times the normal range. In the MWG test, both groups showed changes less than 20% in body temperature and body weight before the after the final immunizations. Inflammatory cytokines within the muscle at the injection site on day 3 after intramuscular injection revealed no significant response in all groups. Conclusion: There were no findings associated with residual PTx, and no significant differences in both local and systemic adverse reactions in the novel rDTaP vaccine compared to existing available DTaP vaccines. The results suggest that the novel rDTaP vaccine is safe.